Miki Ohira

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Papillary Thyroid

Cross Sectional

Dna Damage Response

Top Venues

Pediatric blood & cancer

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer 71 (6) (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer 71 (6) (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer 71 (6) (2024)
Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Hideo Mugishima, Akira Nakagawara
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Pediatric blood & cancer (2024)
Kayoko Tao, Fumito Yamazaki, Takashi Kubo, Kuniko Sunami, Tadashi Kumamoto, Ayumu Arakawa, Masanaka Sugiyama, Yuko Watanabe, Miho Nakajima, Nami Shirakawa, Kazuki Tanimura, Takafumi Koyama, Makoto Hirata, Kazuki Sudo, Noriko Tanabe, Tomoko Watanabe, Teruhiko Yoshida, Mayuko Kitami, Akihiko Yoshida, Yasushi Yatabe, Yoshiko Nakano, Miki Ohira, Takehiko Kamijo, Atsuko Nakazawa, Motohiro Kato, Koichi Ichimura, Takashi Kohno, Noboru Yamamoto, Tomoro Hishiki, Hitotshi Ichikawa, Chitose Ogawa
Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project. JCO precision oncology 7 (2023)
Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafune, Tatsutoshi Nakahata, Hiroaki Kanda, Takehiko Kamijo
Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. Cancer science (2023)
Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafune, Tatsutoshi Nakahata, Hiroaki Kanda, Takehiko Kamijo
Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. Cancer science (2023)
Yoshitaka Shinno, Hisanori Takenobu, Ryuichi P Sugino, Yuki Endo, Ryu Okada, Masayuki Haruta, Shunpei Satoh, Kyosuke Mukae, Dilibaerguli Shaliman, Tomoko Wada, Jesmin Akter, Kiyohiro Ando, Atsuko Nakazawa, Hideo Yoshida, Miki Ohira, Tomoro Hishiki, Takehiko Kamijo
Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN. Cancer science (2022)
Miki Ohira, Yohko Nakamura, Tetsuya Takimoto, Atsuko Nakazawa, Tomoro Hishiki, Kimikazu Matsumoto, Hiroyuki Shichino, Tomoko Iehara, Hiroki Nagase, Takashi Fukushima, Akihiro Yoneda, Tatsuro Tajiri, Akira Nakagawara, Takehiko Kamijo
Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG). Biomolecules 12 (1) (2021)
Jesmin Akter, Yutaka Katai, Parvin Sultana, Hisanori Takenobu, Masayuki Haruta, Ryuichi P Sugino, Kyosuke Mukae, Shunpei Satoh, Tomoko Wada, Miki Ohira, Kiyohiro Ando, Takehiko Kamijo
Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma. Oncogenesis 10 (11) (2021)
Kiyohiro Ando, Miki Ohira, Ichiro Takada, Verna Cázares-Ordoñez, Yusuke Suenaga, Hiroki Nagase, Shinichi Kobayashi, Tsugumichi Koshinaga, Takehiko Kamijo, Makoto Makishima, Satoshi Wada
FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis. Cancer science (2021)
Yuya Terashima, Etsuko Toda, Meiji Itakura, Mikiya Otsuji, Sosuke Yoshinaga, Kazuhiro Okumura, Francis H W Shand, Yoshihiro Komohara, Mitsuhiro Takeda, Kana Kokubo, Ming-Chen Chen, Sana Yokoi, Hirofumi Rokutan, Yutaka Kofuku, Koji Ohnishi, Miki Ohira, Toshihiko Iizasa, Hirofumi Nakano, Takayoshi Okabe, Hirotatsu Kojima, Akira Shimizu, Shiro Kanegasaki, Ming-Rong Zhang, Ichio Shimada, Hiroki Nagase, Hiroaki Terasawa, Kouji Matsushima
Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nature communications 11 (1) (2020)